On July 16, S&P Global held the "Seizing Opportunities, Driving a Sustainable Future—S&P Global Sustainable1 Sustainability Seminar & The Sustainability Yearbook (China Edition) 2024 Launch" event in Beijing. Due to its outstanding performance in the S&P Corporate Sustainability Assessment (CSA), Sino Biopharm stood out from over 1,700 companies to become one of the 129 best-performing companies across various industries to be included. This is also the second consecutive year that Sino Biopharm has been included in the yearbook.

The S&P Global Corporate Sustainability Assessment (CSA) is one of the world's largest annual assessments of corporate sustainability practices and serves as an important basis for global investors' investment decisions and data analysis. The publication of "The Sustainability Yearbook (China Edition)" aims to identify and recognize Chinese enterprises that have demonstrated sustainability advantages in their respective industries. To date, Sino Biopharm's CSA score has steadily increased to 55, surpassing 92% of its global peers and placing it at an internationally leading level.

Sino Biopharm's inclusion in S&P Global's "The Sustainability Yearbook (China Edition)" for the second consecutive year represents the continuous and high recognition of its ESG practical performance by professional institutions in the international capital market. In the future, Sino Biopharm will adhere to its original mission of "Science for a healthier world", continuously integrate the ESG concept with the Group's development strategy, enhance risk management levels, promote stable business growth, and create long-term value for shareholders, patients, employees, and all sectors of society.